Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200

Inclusion Criteria: * Diagnosed with Type I or Type 2diabetes and with a neuropathic diabetic foot ulcer for longer than 8 weeks. * Size of foot ulcer 0.5-13 cm2 * Ulcer graded I by Wager scale * Ulcer is free of necrotic debris, exhibits no signs of clinical infection * Ulcer area blood circulation meets one of the following criteria: A. Palpable tibialis anterior and posterior arteries in the affected foot; B. ABI range \>0.7 to \<1.3; C. TcPO2\>30mmHg Exclusion Criteria: * Ulcer is of non-diabetic pathophysiology * The ulcer has decreased in size by \>=30% after the screening visit (week -2 to -4 before treatment) * Severe hepatic deficiency * Glycated hemoglobin A1C (HbA1C) level of \>12% * Postprandial blood sugar \> 350mg/dl * Require antibiotics to treat the target wound infection within 14 days prior to treatment * Evidence of current wound infection including pus drainage from wound site * Severe renal failure (GFR\<30) including subject on renal dialysis * Pregnant or breastfeeding * Was receiving oral or parenteral corticosteroids, immunosuppressives, or cytotoxic agents prior to 4 weeks from screening * Patient receiving anticoagulation therapy except for aspirin * Underwent wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days prior to screening visit